Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Insulin Makers To FDA: Clarify 'Transition' Impact On Drug/Biologic Combos

Executive Summary

Agency also must address whether certain protein products previously approved as NDAs could be deemed standalone BLAs or biosimilars, PhRMA and BIO say.



Related Companies